Literature DB >> 8834048

X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant.

E Pegoraro1, V Carelli, M Zeviani, P Cortelli, P Montagna, P Barboni, C Angelini, E P Hoffman.   

Abstract

Leber's hereditary optic neuropathy (LHON) accounts for about 3% of the cases of blindness in young adult males. The underlying mitochondrial pathogenesis of LHON has been well studied, with specific mitochondrial DNA (mtDNA) mutations of structural genes described and well characterized. However, enigmatic aspects of the disease are not explained by mutation data, such as the higher proportion of affected males, the later onset of the disease in females, and the presence of unaffected individuals with a high proportion of mutant mtDNA. A hypothesis which has been put forward to explain the unusual disease expression is a dual model of mtDNA and X-linked nuclear gene inheritance. If a nuclear X-linked modifier gene influences the expression of the mitochondrial-linked mutant gene then the affected females should be either homozygous for the nuclear determinant, or if heterozygous, lyonization should favor the mutant X. In order to determine if an X-linked gene predisposes to LHON phenotype we studied X-inactivation patterns in 35 females with known mtDNA mutations from 10 LHON pedigrees. Our results do not support a strong X-linked determinant in LHON cause: 2 of the 10 (20%) manifesting carriers showed skewing of X-inactivation, as did 3 of the 25 (12%) nonmanifesting carriers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834048     DOI: 10.1002/(SICI)1096-8628(19960202)61:4<356::AID-AJMG10>3.0.CO;2-R

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

Review 1.  Mitochondrial DNA analysis: polymorphisms and pathogenicity.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

2.  Clinical and electrophysiological recovery in Leber hereditary optic neuropathy with G3460A mutation.

Authors:  Eamon Sharkawi; Justyna D Oleszczuk; Graham E Holder; Joyti Raina
Journal:  Doc Ophthalmol       Date:  2012-06-10       Impact factor: 2.379

3.  Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder.

Authors:  Gavin Hudson; Sharon Keers; Patrick Yu-Wai-Man; Philip Griffiths; Kirsi Huoponen; Marja-Liisa Savontaus; Eeva Nikoskelainen; Massimo Zeviani; Franco Carrara; Rita Horvath; Veronika Karcagi; Liesbeth Spruijt; I F M de Coo; Hubert J M Smeets; Patrick F Chinnery
Journal:  Am J Hum Genet       Date:  2005-10-11       Impact factor: 11.025

4.  Diffuse cortical atrophy in a patient with Turner syndrome and Leber hereditary optic neuropathy.

Authors:  Pierre Blaise; Arnaud Fumal; Nicolas Janin; Alain Verloes; Gustave Moonen; Cécile Andris
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 5.  Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve?

Authors:  N Howell
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

Review 6.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 7.  Leber hereditary optic neuropathy.

Authors:  P Yu-Wai-Man; D M Turnbull; P F Chinnery
Journal:  J Med Genet       Date:  2002-03       Impact factor: 6.318

Review 8.  A review of primary hereditary optic neuropathies.

Authors:  M Votruba; S Aijaz; A T Moore
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 9.  Inherited mitochondrial optic neuropathies.

Authors:  P Yu-Wai-Man; P G Griffiths; G Hudson; P F Chinnery
Journal:  J Med Genet       Date:  2008-11-10       Impact factor: 6.318

Review 10.  Therapeutic Options in Hereditary Optic Neuropathies.

Authors:  Giulia Amore; Martina Romagnoli; Michele Carbonelli; Piero Barboni; Valerio Carelli; Chiara La Morgia
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.